| Project/Area Number |
11557194
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 展開研究 |
|---|
| Research Field |
医薬分子機能学
|
|---|
| Research Institution | The University of Tokushima |
|---|
Principal Investigator |
KIWADA Hiroshi The University of Tokushima, Faculty of Pharmacetical Sciences, Professor, 薬学部, 教授 (50120184)
|
|---|
| Project Period (FY) |
1999 – 2001
|
| Project Status |
Completed (Fiscal Year 2001)
|
| Budget Amount *help |
¥12,700,000 (Direct Cost: ¥12,700,000)
Fiscal Year 2001: ¥2,700,000 (Direct Cost: ¥2,700,000)
Fiscal Year 2000: ¥4,000,000 (Direct Cost: ¥4,000,000)
Fiscal Year 1999: ¥6,000,000 (Direct Cost: ¥6,000,000)
|
|---|
| Keywords | Liposomes / Adjuvant / vaccine / cetylmannoside / FCA / マンノース |
|---|
| Research Abstract |
We showed that the liposomes which were modified with cetylmannoside (Man-MLV) could be one of promising candidates for the adjuvant, possible to use for human. We prepared some kinds of liposomes to study which physicochemical properties of the liposomes decide their adjuvant ability. Consequently, the liposomes that have rigid membrane, 200nm in a diameter and being modified with 30 mol % cetylmannoside, showed most activity to produce specific antibody against BSA encapsulated into the liposomes. It is most likely that the liposomes efficiently delivered the encapsulated antigen (BSA) into phagocytic cells such as macrophages via complement-receptor mediated endocytosis, resulting in increased the specific antibody titer in serum. In addition, the Man-MLV (30 mol %) showed the ability to induce cytokine release from peripheral blood cells following incubation with human whole blood. In conclusion, the Man-MLV (30 mol %) have remarkable ability to induce antigen-specific antibody by increasing uptake of the antigen by phagocytic cells as well as stimulating immune system.
|
